Antimicrobial resistance profiles of Acinetobacter baumannii strains isolated in intensive care units
Abstract number: 1734_151
Naim M., Chabani M., Tiouit D.
Objectives:Acinetobacter baumannii formely bacterium saprophyte is at present a redoubtable nosocomial pathogen in intensive care units (ICU) because its virulence and of its multidrug resistance. The purpose of this short study is to estimate the profiles resistance of Acinetobacter baumannii isolated in military hospital's ICU during 3 months.
Methods: 20 strains isolated in different samples obtained from inpatients hospitalised in ICU over a period going from January till March 2006. The identification of Acinetobacter baumannii was performed using classical bacteriological methods (API 10S, API 20NE boiMérieux) associated to the other additional tests (incubation 44°C, catalase...). The antimicrobial susptibility testing were performed using NCCLS methods. Twelve common used antimicrobial agents were tested: ticarcillin (TIC), piperacillin (PIP), ceftazidim (CAZ), imipenem (IMP), gentamicin (GM), amikacin (AN), trimethoprim-sulfamethoxazol (SXT), ticarcillin+clavulanic acid (TCC), ciprofloxacin (CIP), netilmicin (NET), tobramycin (TB), colistin (CS).
Results: The isolates included in our study originated from: wounds (45%), urine (25%), bronchial aspirates (20%), haemocultures (10%). The almost totality of strains presented a simultaneous multidrug resistant to 8 antibiotics with rates from 70100%: TIC 100%, PIP 100%, AN 100%, GM 100%, CAZ 95%, IMP 80%, TCC 70%, SXT 70%.
The rates of resistance to other antibiotics were included between 4555% (TOB, NET, CIP)
Colistin were the only antimicrobial agent active to all isolated strains.
Conclusions: These results show distrubing emergence and fast evolution of multidrug resistant in our hospital, that what we have been reported in a poster published in ECCMID 2005.
Is important to say that multidrug resistant concern the major antibiotics as imipenem and amikacin often ending in a therapeutic impasse and a fatal outcome
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|